When a new drug or vaccine first come to market, we don’t know much about them. New side effects might appear when they are used in the wider population. Strong safety monitoring systems are needed so that regulators know where to look for signs of possible harm.
As the WHO Collaborating Centre for International Drug Monitoring, we work with countries around the world to build up national pharmacovigilance systems in line with their needs. With our tools even those with the most limited resources can boost both the volume and quality of reporting and the analysis of adverse event data for regulatory decisions.
What’s more, by sharing data with other countries through VigiBase, the world’s largest database of adverse event reports, they contribute to strengthening patient safety globally.
Be alert, vigilant and quick to react
When a medicine is released onto the market safety concerns can still arise. Effective systems are needed to identify the first signs of emerging issues. VigiFlow supports the collection and processing of adverse event reports that are critical for a national pharmacovigilance system to function properly.
Any form, anytime, anyplace
A country’s national pharmacovigilance system is only as strong as its data. Our digital reporting forms help national regulatory authorities get the information they need from patients, health workers, and industry to make informed decisions quickly.
Signal detection without borders
VigiLyze supports the entire signal detection management process, allowing you to analyse and document your work in one place. With VigiLyze, you can make disproportionality calculations based on your own data or a group of countries since the global data is never more than a click away.
Take control of your data
VigiFlow and VigiLyze also give you access to WHODrug Global, the world’s most comprehensive drug coding dictionary. Identify the medicines referenced in adverse event reports, including what they contain, regardless of trade name or where in the world the medicines were used.